Poised for robust growth
Alkem Labs is a leading Indian pharmaceutical company engaged in the manufacturing of branded generics, generic drugs, active pharmaceutical ingredients (“APIs”) and Nutraceuticals. Indian business contributes 73% to overall sales while international business contributes for the rest.
View & Valuvation:
We expect revenue and PAT to grow at a CAGR of 18.5 & 21.7% respectively over FY16-19E. Further, EBITDA margin is expected to improve by 280bps on account of increasing launches in chronic products coupled with consolidation in acute therapies. Hence, we initiate Alkem with a BUY rating with a TP of Rs.1926 based on 19x FY19E EPS.
Research Report Alkem Laboratories Ltd
Investments in equity shares, debentures, etc., are not obligations of, or guaranteed by Wealth India Financial Services Pvt. Ltd., and are subject to investment risks. Click here to read our full disclaimer.
- Merger of Navi Overnight Fund into Navi Liquid Fund and Navi Conservative Hybrid Fund into Navi Aggressive Hybrid Fund
- Intimation of suspension of subscription in Bandhan US Equity Fund of Fund
Winning Funds, Losing Streaks: Decoding the Mystery of Short-Term Underperformance
Wealth Conversations – November 2024- Notice of Change in Fundamental Attributes of DSP Equity & Bond Fund and DSP Quant Fund
Superb analysis.
Keep up the good work FundsIndia.
Superb analysis.
Keep up the good work FundsIndia.